Results presented at TCT meeting demonstrate the benefits of TriClip for tricuspid regurgitation
Abbott announced data from five late-breaking presentations showing the benefits of its minimally invasive devices in treating people with a range of structural heart diseases
Data include findings that reinforce the value of MitraClip, the world's first and leading transcatheter edge-to-edge repair (TEER) device, to treat leaky valves in people with mitral regurgitation (MR). ( see separate entry) The new data around Abbott's structural heart therapies were presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation in Boston (September 16-19, 2022).
Results were also presented on TriClip, the first therapy designed specifically for tricuspid heart valve repair; the Amplatzer Amulet Left Atrial Appendage Occluder, a minimally invasive option offering the most complete closure of the left atrial appendage (LAA) to reduce risk of stroke; and Portico, a self-expanding transcatheter aortic valve implantation (TAVI) system.
Structural heart diseases such as valve disease or openings in the heart that require closure can impair how the heart moves blood through the body. New minimally invasive technology has changed how physicians approach patient care and limits the need for more complex or risky surgery.
First Results from the TriClip TRILUMINATE Pivotal Trial : TRILUMINATE Pivotal is the first randomized, controlled clinical trial evaluating the safety and effectiveness of TEER with TriClip in 700 patients with severe TR in the U.S., Canada and Europe. The data from the roll-in cohort through 30 days show: i. High implant success rate (99%). ii. At least a one-grade TR reduction in 91% of patients, with moderate or less residual TR achieved in 74%. iii. Patients achieving around a 17-point improvement in the KCCQ score, a 30% improvement from baseline score, which demonstrates a substantial improvement in their quality of life.
Related news and insights
Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's Evoque transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.
Edwards Lifesciences Corporation announced that it has received CE Mark for the Edwards Pascal transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation.